All sponsors

Vertex Pharmaceuticals Incorporated $VRTX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS24
PHASE 3 / 2-318
RECRUITING7
READOUTS ≤12 MONTHS11
READOUT SLIPPED >6 MO48%

Delay Index: of 21 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.1 months). See all sponsors →

Open Vertex Pharmaceuticals Incorporated on the live radar map → 📅 $VRTX readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Biological/Vaccine
NCT06832410
P3RecruitingType 1 Diabetes; Kidney Transplant102026-09-17
VX-121/TEZ/D-IVA
NCT05444257
P3Active, not recruitingCystic Fibrosis8222026-10-30 (+13 mo)
Suzetrigine
NCT06696443
P3Active, not recruitingDiabetic Peripheral Neuropathic Pain4552027-01-25
Galileo
NCT06185764
P1/2Active, not recruitingMyotonic Dystrophy Type 1 (DM1)472027-02-02 (+2 mo)
VX-264
NCT05791201
P1/2Active, not recruitingType 1 Diabetes72027-03-12 (+10 mo)
VX-993
NCT06619860
P2RecruitingDiabetic Peripheral Neuropathic Pain3002027-03-25 (+12 mo)
ELX/TEZ/IVA
NCT05331183
P3Active, not recruitingCystic Fibrosis2972027-04-06 (+25 mo)
Suzetrigine
NCT07231419
P3RecruitingDiabetic Peripheral Neuropathic Pain7342027-04-06
Suzetrigine
NCT06628908
P3RecruitingDiabetic Peripheral Neuropathic Pain11002027-05-31
CTX001
NCT05329649
P3Active, not recruitingSickle Cell Disease; Hydroxyurea Failure132027-06-06 (+13 mo)
CTX001
NCT05477563
P3RecruitingBeta-Thalassemia; Thalassemia262027-06-09 (+28 mo)
AGLOW
NCT07161037
P2Active, not recruitingAutosomal Dominant Polycystic Kidney Disease (ADPKD)262027-07-22
ELX/TEZ/IVA
NCT06460506
P3Active, not recruitingCystic Fibrosis502027-09-30
CTX001
NCT05356195
P3Active, not recruitingBeta-Thalassemia; Thalassemia162027-11-14 (+18 mo)
Povetacicept
NCT07890909
P3Not yet recruitingImmunoglobulin A Nephropathy402027-12-12
VX-880
NCT04786262
P3RecruitingDiabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness572027-12-31 (+48 mo)
AMPLITUDE
NCT05312879
P2/3Active, not recruitingProteinuric Kidney Disease5222028-06-02 (+25 mo)
OLYMPUS
NCT07204275
P2/3RecruitingPrimary Membranous Nephropathy1762028-12-29
VX-670
NCT06926621
P2Enrolling by invitationMyotonic Dystrophy Type 1 (DM1)442029-01-30 (+6 mo)
ETNA
NCT07501702
P2Active, not recruitingMyasthenia Gravis, Generalized342029-03-02
VNZ/TEZ/D-IVA
NCT05844449
P3Enrolling by invitationCystic Fibrosis1742029-07-30 (-14 mo)
Povetacicept
NCT07807995
P3Enrolling by invitationImmunoglobulin A Nephropathy6052029-12-28
VX-121/TEZ/D-IVA
NCT05422222
P3Active, not recruitingCystic Fibrosis2102030-06-30
CTX001
NCT04208529
P3Enrolling by invitationBeta-Thalassemia; Thalassemia1602039-09-30